BioDrugs (2019) 33:589 594 https://doi.org/10.1007/s40259-019-00378-x CORRECTION Correction : Efficacy and Safety of Supportive Care Biosimilars Among Patients: A Systematic Review and Meta Analysis Jichun Yang 1 Shuqing Yu 1 Zhirong Yang 2 Yusong Yan 1 Yao Chen 1 Hongmei Zeng 3 Fei Ma 4 Yanxia Shi 5 Yehui Shi 6 Zilu Zhang 7 Feng Sun 1 Published online: 21 September 2019 Springer Nature Switzerland AG 2019 Correction : BioDrugs (2019) 33:373 389 https ://doi.org/10.1007/s4025 9-019-00356-3 The authors unintentionally included in the meta-analysis both the initial abstract and the final paper of the by Puerlas et al. [45, 48]. In order remove this duplication, the following corrections are required. Page 373, abstract, results, line 1: The following sentence, which previously read: We identified 29 studies that compared of G-CSF or epoetin alfa: one RCT and five cohort studies (tal N = 2816) of epoetin alfa, and 13 RCTs and 10 cohort studies (tal N = 23,561) of G-CSF. should read: We identified 28 studies that compared of G-CSF or epoetin alfa: one RCT and five cohort studies (tal N = 2816) of epoetin alfa, and 13 RCTs and 9 cohort studies (tal N = 23,043) of G-CSF. The original article can be found online at https ://doi.org/10.1007/ s4025 9-019-00356-3. * Feng Sun sunfeng@bjmu.edu.cn Jichun Yang yangjichunya@163.com Shuqing Yu yushuqing@hsc.pku.edu.cn Zhirong Yang fsyz30147@163.com Yusong Yan yyan21@its.jnj.com Yao Chen 1310306223@pku.edu.cn Hongmei Zeng hongmeizeng2011@163.com Fei Ma drmafei@126.com Yanxia Shi shiyx@sysucc.org.cn Yehui Shi shiyehui@tjmuch.com Zilu Zhang Zilu.zhang.us@gmail.com 1 Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China 2 Primary Care Unit, School of Clinical Medicine, University of Cambridge, Cambridgeshire CB1 8RN, UK 3 Department of Registry, National Center/National Clinical Research Center for / Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China 4 Department of Medical Oncology, National Center/National Clinical Research Center for / Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China 5 Department of Medical Oncology, Sun Yat-Sen University Center/State Key Laborary of Oncology in South China/Collaborative Innovation Center for Medicine, Guangzhou 510060, China 6 7 Phase I Clinical Trial Department of Tianjin Medical University Institute and Hospital, Tianjin 300060, China Harvard Medical School and Harvard Pilgrim Health Care Institute, Bosn, MA 02215, USA Vol.:(0123456789)
590 J. Yang et al. Page 377, fig. 1, the following text, which previously read: Box 8: Full-text excluded (n = 211) should read Fulltext excluded (n = 212) Duplicates: 91 should read Duplicates 92 Box 9: Full-text articles assessed for eligibility (n = 29) should read Full-text articles assessed for eligibility (n = 28) Box 10: Studies included in qualitative synthesis (n = 29) should read Studies included in qualitative synthesis (n = 28) Box 11: Studies included in quantitative synthesis (n = 29) should read Studies included in quantitative synthesis (n = 28) G-CSF :13 RCTs + 10 studies should read G-CSF :13 RCTs + 9 studies A corrected version of Fig. 1 is shown below: Page 379, Table 1, G-CSF vs. G-CSF section, Puerlas et al. (2016) [45] row: the entire row should be deleted. Page 379, Table 1, G-CSF vs. G-CSF section, Puerlas et al. (2018) [48] row: The cell entry in column 4 Sample size (B/R), which previously read 303/215 should read 49/49. Page 380, Table 1, G-CSF vs. G-CSF section, patients of cohort studies row: the cell entry in column 4 Sample size (B/R), which previously read 2677/17,739 should read 2374/17,524. Page 381, section 3.2.2, paragraph 1, line 1: The sentence, which previously read: Ten cohort studies (2677 patients vs 17,739 patients) should read Nine cohort studies (2374 patients vs 17,524 patients). Fig. 1 PRISMA flowchart of included studies. G-CSF granulocyte colony-stimulating facrs, randomized controlled trial
Efficacy and Safety of Supportive Care Biosimilars Among Patients Page 381, section 3.2.2, paragraph 3, line 10: The sentence, which previously read In addition, five cohort studies [40, 41, 45, 48, 49] compared the incidence of FN in cycle 1 in patients treated with filgrastim (860 patients) and filgrastim (6970 patients). should read In addition, four cohort studies [40, 41, 48, 49] compared the incidence of FN in cycle 1 in patients 591 treated with filgrastim (557 patients) and filgrastim (6755 patients). Page 382, Table 3, FN incidence in cycle 1 (3 wk) section, : the s in the / row and the row have been corrected. A corrected version of the table is shown below with the corrected text shown in bold. Table 3 Results for G-CSF Outcomes (follow-up time) Study Group facrs Subgroup No. Sample size (B/R) Heterogeneity test I 2 p Results of meta-analysis Summary effects 95% CI p p-value between subgroups GRADE evidence FN incidence in cycle 1 (3 wk) Drug 4 [53, 56 58] 470/352 10.8% 0.339 RR = 1.09 0.72 1.65 0.19 0.22 Low 4 [28, 50, 51, 59] 582/515 0.0% 0.81 RR = 1.14 0.73 1.79 0.57 5 [28, 50, 56, 57, 59] 738/713 0.0% 0.90 RR = 1.14 0.80 1.63 0.47 0.22 NSCLC 2 [51, 53] 251/125 0.0% 0.64 RR = 1.53 0.80 2.93 0.19 NHL 1 [58] 63/29 RR = 0.54 0.20 1.46 0.22 G-CSF 8 [28, 50, 51, 53, 55 59] 1052/867 0.0% 0.74 RR = 1.09 0.80 1.49 0.58 2 [40, 48] 196/183 0.0% 0.28 RR = 1.60 0.85 3.01 0.15 0.43 Moderate NHL 1 [41] 12/26 RR = 0.87 0.20 3.85 0.85 Nonmyeloid 1 [49] 349/6546 RR = 0.97 0.46 2.05 0.93 4 [40, 41, 48, 49] 557/6755 0.0% 0.35 RR = 1.25 0.79 1.98 0.35
592 J. Yang et al. Outcomes (follow-up time) Study Group facrs Subgroup No. Sample size (B/R) Heterogeneity test I 2 p Results of meta-analysis Summary effects 95% CI p p-value between subgroups GRADE evidence DSN in cycle 1 (3 wk) 7 [28, 50, 52, 54, 57, 1092/975 0.0% 0.70 WMD = 0.03 0.07 0.13 0.50 0.27 Moderate NHL 1 [58] 63/29 WMD = 0.40 1.17 0.37 0.31 Drug 3 [54, 57, 58] 386/260 0.0% 0.37 WMD = 0.06 0.12 0.23 0.53 0.70 Moderate 5 [28, 50, 52, 769/744 0.0% 0.58 WMD = 0.01 0.11 0.13 0.83 G-CSF 8 [28, 50, 52, 54, 57 60] 1155/1004 0.0% 0.66 WMD = 0.03 0.07 0.13 0.59 Time ANC recovery in cycle 1 (3 wk) 4 [50, 52, 59, 60] 587/569 28.7% 0.24 WMD = 0.07 0.10 0.24 NSCLC 1 [51] 93/46 WMD = 0.07 1.41 1.27 0.42 0.84 Moderate 0.92 5 [49 52, 680/615 5.8% 0.37 WMD = 0.07 0.10 0.24 0.43 NHL 1 [41] 12/26 WMD = 0.14 0.42 0.70 0.63 Low Bone pain rate (3 30 wk) 2 [54, 59] 512/355 80.9% 0.02 RR = 0.89 0.76 1.03 NSCLC 1 [53] 158/79 RR = 1.20 0.44 3.29 0.12 0.63 Moderate 0.72 Various tumors 1 [55] 54/54 RR = 1.25 0.53 2.92 0.61 4 [53 55, 59] 724/488 51.3% 0.10 RR = 0.90 0.78 1.05 0.18 Various tumors 4 [42 44, 46] 123/309 0.0% 0.61 RR = 0.86 0.59 1.24 0.41 Moderate
Efficacy and Safety of Supportive Care Biosimilars Among Patients 593 Outcomes (follow-up time) Study Group facrs Subgroup No. Sample size (B/R) Heterogeneity test I 2 p Results of meta-analysis Summary effects 95% CI p p-value between subgroups GRADE evidence ADE rate (3 30 wk) Drug 4 [29, 54, 56, 60] 674/412 6.3% 0.36 RR = 1.03 0.97 1.09 0.35 Moderate 3 [29, 51, 59] 579/463 61.8% 0.07 RR = 0.98 0.95 1.01 0.24 0.16 6 [28, 29, 54, 56, 59, 60] 1158/825 32.8% 0.19 RR = 0.99 0.96 1.02 0.61 0.08 NSCLC 1 [51] 95/50 RR = 0.92 0.50 1.71 0.40 G-CSF 7 [28, 29, 51, 54, 56, 1253/875 42.4% 0.10 RR = 0.98 0.95 1.02 0.39 Various tumors 1 [47] 1694/10,460 RR = 1.08 0.89 1.31 0.43 Moderate ADE adverse drug event, ANC absolute neutrophil count, B/R /reference biologics, CI confidence interval, DSN duration of severe (grade 4) neutropenia, FN febrile neutropenia, G-CSF granulocyte colony-stimulating facrs, GRADE Grading of Recommendations Assessment, Development and Evaluation, NHL non-hodgkin s lymphoma, No. number of included studies, NSCLC nonsquamous non smallcell lung, randomized controlled trial, RR risk ratio, WMD weighted mean difference Page 384, Fig. 3, FN incidence in cycle1.cohort section, subgroup: the text in the Study number column that previously read 3 should read 2 ; the text in the Biosimilar sample size column that previously read 499 should read 196 ; the text in Reference sample size column that previously read 398 should read 183 ; the text in the P of meta-analysis column that previously read 0.22 should read 0.15 ; the text in the P between sub-groups column that previously read 0.68 should read 0.43 ; the text in the ES (95% CI) column that previously read 1.36 (0.84, 2.23) should read 1.60 (0.85, 30.1). Page 384, Fig. 3, FN incidence in cycle1.cohort section, F row: the text in the Study number column that previously read 5 should read 4 ; the text in the Biosimilar sample size column that previously read 860 should read 557 ; the text in Reference sample size column that previously read 6970 should read 6755 ; the text in the P of meta-analysis column that previously read 0.36 should read 0.35 ; the text in the ES (95% CI) column that previously read 1.20 (0.81, 1.78) should read 1.25 (0.79, 1.98). A corrected version of Fig. 3 is shown below.
594 J. Yang et al. Fig. 3 Meta-analysis of G-CSF biosimilar drugs vs G-CSF drugs. ADE at least one adverse drug event, ANC absolute neutrophil count, CI confidence interval, DSN duration of severe (grade 4) neutropenia, ES effect size, F filgrastim, FN febrile neutropenia, G-CSF granulocyte colony-stimulating facrs, NHL non-hodgkin s lymphoma, NSCLC nonsquamous non small-cell lung, P pegfilgrastim, randomized controlled trial, RR risk ratio, WMD weighted mean differences Page 388, Reference # 45: This reference should be deleted. the text in column patient that previously read 7830 should read 7312 Electronic Supplementary Material, Supplementary Table 3, Puerlas et al. 2016 [25] row: this row should be deleted. Electronic Supplementary Material, Supplementary Table 5, FN incidence in cycle1 row: the text in column that previously read 5 [20, 21, 25, 27, 28] should read 4 [20, 21, 27, 28] Electronic Supplementary Material, page 9, reference #25: this reference should be deleted